Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings

Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C., Izard, S., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., Saqi, A., Grindheim, J., Schulze, K., Sonett, J. R., Rizvi, N. A., Izar, B., Taylor, A. M., & Shu, C. A. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer, 12(12), e009301. https://doi.org/10.1136/jitc-2024-009301
Authors:
Brian S. Henick
Peter D. Koch
Justin F. Gainor
Mark M. Awad
Codruța Chiuzan
Stephanie Izard
Yohanna Georgis
Samyukta Mallick
Robert F. Garofano
Cheryl V. Wong
Anjali Saqi
Jessica Grindheim
Katja Schulze
Joshua R. Sonett
Naiyer A. Rizvi
Benjamin Izar
Alison M. Taylor
Catherine A. Shu
Affiliated Authors:
Brian S. Henick
Peter D. Koch
Yohanna Georgis
Samyukta Mallick
Robert F. Garofano
Anjali Saqi
Joshua R. Sonett
Naiyer A. Rizvi
Benjamin Izar
Alison M. Taylor
Catherine A. Shu
Author Keywords:
lung cancer
immunotherapy
neoadjuvant
biomarker
Publication Type:
Article
Unique ID:
10.1136/jitc-2024-009301
PMID:
Publication Date:
Data Source:
OpenAlex

Record Created: